The 71% Wound Care revenue collapse from Medicare changes is the dominant driver, and the lowered 2026 guidance suggests no near-term recovery. Monitor Q4 2026 for sequential Wound Care stabilization and progress on the Sanara acquisition closing, which could shift the business mix further toward Surgical.
Price Chart
Executive Summary
MiMedx reported Q3 2026 net sales of $62M, down 45% YoY from $114M, driven by a 71% decline in Wound Care sales due to Medicare reimbursement changes. Surgical sales grew 9% YoY to $40M. GAAP net loss was $9M vs net income of $17M a year ago. The company returned to positive Adjusted EBITDA of $2.1M (3.3% margin) and ended the quarter with no debt. Management lowered 2026 net sales guidance to $250-260M. A $25M patent license agreement was signed, and a favorable court ruling was obtained in the AXIOFILL regulatory classification case.
Key Financial Metrics
Key Facts
- Q3 2026 net sales $62.3M, down 45% YoY from $113.7M
- Wound Care sales $22.3M, down 71% YoY due to Medicare reimbursement changes
- Surgical sales $40.0M, up 9% YoY
- GAAP net loss $8.7M vs net income $16.7M in Q3 2025
- Adjusted EBITDA $2.1M (3.3% margin), positive for the first time in 2026
- 2026 net sales guidance lowered to $250-260M from prior expectations
- Cash and cash equivalents $120.8M, no debt outstanding after repaying $17M term loan
- Patent license agreement with wound care competitor for $25M total, first $5M received
- Favorable federal court ruling vacating FDA's classification of AXIOFILL, remanded for further consideration
- Proposed acquisition of Sanara MedTech pending HSR clearance
Financial Impact
Revenue decline of $51.4M (45%) YoY; GAAP net income swing of $25.4M from +$16.7M to -$8.7M; guidance lowered to $250-260M for full year 2026
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Surgical | $40.0M | +9.1% |
| Wound | $22.3M | -71.0% |
Risk Factors
- Wound Care revenue may continue to decline as Medicare reimbursement changes take full effect
- Proposed Sanara acquisition faces regulatory delay and integration risk
- GAAP net loss and negative free cash flow ($5.6M YTD) raise liquidity concerns despite no debt
- Patent license agreement payments are spread over five years, limiting near-term cash benefit
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3390724 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 1d ago | 8-K | No price | awaiting T+5 | awaiting T+5 | No price |
Oct 28, 2026 1d ago | Press Release | $3.95 | awaiting T+5 | awaiting T+5 | $3.97 (−0.51%) |
Oct 28, 2026 1d ago | Press Release | $3.95 | awaiting T+5 | awaiting T+5 | $3.97 (+0.51%) |
Oct 16, 2026 13d ago | 425 | $4.43 $3.91 | ▼ −11.74% | ▼ −11.83% | $3.97 (−10.38%) |
Oct 16, 2026 13d ago | 8-K | $4.43 $3.91 | ▲ +11.74% | ▲ +11.83% | $3.97 (+10.38%) |
Jun 2, 2026 21w ago | Court Ruling | $3.57 $3.71 | ▲ +3.92% | ▲ +6.89% | $3.97 (+11.20%) |
Apr 29, 2026 26w ago | DEFA14A | $3.36 $3.66 | ▲ +8.93% | ▲ +7.20% | $3.97 (+18.15%) |
Apr 22, 2026 27w ago | Press Release | $3.31 $3.27 | ▼ −1.36% | ▼ −1.41% | $3.97 (+19.94%) |
Apr 16, 2026 28w ago | 8-K | $3.43 $3.35 | ▲ +2.33% | ▲ +3.32% | $3.97 (−15.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers